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Repeated measurements of human chorionic gonadotrophin
(hCG) are used to monitor the effect of treatment in patients with
hCG-producing testicular cancer. Following chemotherapy, the
disappearance of hCG from serum is assumed to follow first-order
kinetics with a fixed half-life of fewer than 3 days (Bosl et al,
1981; Toner et al, 1990; Motzer et al, 1992, 1993; Bosl and
Chaganti, 1994; Bosl and Head, 1994; Murphy et al, 1994). As
factors like changes in volume of distribution, treatment-induced
organ toxicity, weight loss and repeated blood transfusions could
influence the disappearance of hCG, we assumed the expected
monoexponential decline to be a too simple model. In order to
study the hCG elimination during chemotherapy, we recently
introduced  125I-hCG as an elimination marker and found that the
disappearance of 125I-hCG and immunologically measured hCG
was quite different from the commonly used monoexponential
model with a half-life of less than 3 days (Christensen et al, 
1999).
After injection of 3 MBq 125I-hCG intravenously (i.v.), serum
samples were drawn at defined time intervals and analysed for
hCG content using an immunofluorometric assay. Radioactivity
for the same samples was measured in parallel in a g-counter.
Serum disappearance curves for 125I-hCG and hCG were plotted. If
the disappearance curves showed a similar pattern, we interpreted
the slow disappearance as caused by a slow elimination rather than
a production of hCG from vital tumour cells.
125I-hCG is a well-known reagent in clinical biochemistry and is
used extensively in hCG assays. Previous studies have shown that
the iodination process leaves the hCG molecule mainly intact (Catt
et al, 1972). During iodination, two epitopes on the a chain are
destroyed (Berger et al, 1988). The structural integrity of hCG and
its ability to bind to specific antibodies and LH/hCG receptors is
well retained after iodination. After bolus injection of 125I-hCG
and hCG into rats, no difference in disappearance was seen
(Markkanen et al, 1980).
The present investigations were initiated to answer the
following questions of importance for the utilization of 125I-hCG as
an elimination marker:
Does iodination of hCG affect its elimination in humans?
Does the drop of radioactivity in serum reflect elimination of
125I-hCG, metabolites, or dissociation of 125I from injected
125I-hCG i.v.?
MATERIALS AND METHODS
The study was approved by the local ethics committee and all
volunteers gave their informed written consent before entering the
study.
Iodination of hCG
The hCG used for labelling was supplied by LEO Pharmaceutical
Co., Denmark. The crude hCG was obtained from the urine of
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pregnant women and delivered without additives. LEO used the
crude hCG as raw material for their human ovary luteinizing
hormone (LH)-stimulating pharmaceutical Physex®. The hCG was
purified to 3000 IU mg–1, sterilized, tested for pyrogens, oestro-
gens and abnormal toxicity, and conformed according to (Council
of Europe, 1986). The labelling of the hCG was carried out by
Isopharma A/S, Kjeller, Norway. The following procedure was
used: for labelling 1.5 ml hCG (1 mg ml–1) were dissolved in
0.01 M phosphate-buffered saline (PBS), pH 7.4, mixed with
90 MBq Na125I in a tube containing 60 mg iodogen®. The mixture
was allowed to incubate for 10 min before it was transferred to an
empty tube. For purification, the reaction mixture was then applied
to a PD-10 column (Pharmacia, Sephadex G-25, medium coarse),
equilibrated with 1 mg human serum albumin (HSA) ml–1 PBS and
eluted with 1 mg HSA ml–1 PBS. Following the first 2.5 ml, eight
fractions of 0.5 ml each were collected. Fractions with less than
2% iodide were collected, mixed and diluted to 2 MBq ml–1 with
1 mg HSA ml–1 PBS. The purification procedure was carried out
twice. The product was sterile filtered using a 0.22 mm filter
(Durapore), tested for radiochemical purity, using high-voltage-
electrophoresis on the day of production, and for pH, pyogens and
bacterial growth 14 days after production. The 125I-hCG used had a
labelling per cent of > 88%, radiochemical purity with < 1.7%
iodide, no detectable contamination with 125I-albumin, specific
activity 50–60 MBq mg–1, pH 7.0–7.5, and was sterile and free of
pyogens (LAL < 175 EU 20 ml–1).
High-voltage-electrophoresis was used to test the radiochemical
stability of 125I-hCG following incubation at 4°C for 5, 7, 14, 20
and 29 days respectively. The iodide content was < 5%. To inves-
tigate the influence of the iodination process on the integrity of
hCG, one sample of hCG was taken through the same procedure
for labelling except for the iodogen and iodination step. The
product was then analysed for intact hCG and free b-hCG
following 18 days of storage using immunofluorometric assays. In
the labelled and unlabelled product, intact hCG concentrations of
42 000 IU l–1 and 56 000 IU l–1 and free b-hCG concentrations of
270 IU l–1 and 550 IU l–1, respectively, were found. Differences in
concentrations are caused by difference in the dilution step.
Dosimetry
After injection of 2.66 MBq of 125I-hCG in a healthy normal male,
serum samples were obtained once a day for 21 days. The plasma
disappearance curve of activity from 125I counted in the spectrum
of 15–75 KeV was constructed. The data were fitted a triexponen-
tial model minimizing least squares using non-linear regression
according to the Marquardt–Levenberg method. Area under curve
was calculated. Assuming the total activity was deposited in the
patient, a volume of distribution of 7.3l, the total accumulated
radiation dose was calculated to be < 0.05 mSv following injection
of 3 MBq 125I-hCG.
Elimination of 125I-hCG in normal healthy subjects
Giving 400 mg KI orally at least 1 h before injection of 125I-hCG
prevented thyroid uptake of 125I. A well-functioning i.v. catheter
was placed in the cubital vein of the subject. Serum samples were
drawn prior to injection of 125I-hCG to determine background
activity. Then, 3 MBq 125I-hCG (Isopharma A/S, Kjeller, Norway)
were given as a single i.v. bolus injection. The specific activity of
the labelled hCG was 50 MBq mg–1 and the concentration was
3000 IU mg–1. Thus, the quantity of hCG given was 180 IU. The
elimination of hCG was studied in two ways:
(a.) Immunologically by measuring the plasma disappearance of
the total hCG, using a modified Wallac immunofluorometric
assay. The assay was modified by doubling the sample
volume and changing detecting antibody to INN-hFSH-158
specific for the a-chain epitope a5. The capturing antibody
used was INN-hCG-2 specific for the b-chain epitope b5
(Dirnhofer et al, 1994). The sensitivity was 0.1 IU l–1 (3.IS)
and LH cross-reactivity 0.4%.
(b.) By measuring the rate of plasma disappearance of activity of
125I. Radioactivity was measured in a well counter (COBRA
auto gamma, Packard, USA) set to detect within the energy
range 15–75 KeV. The background activity has been
subtracted from all the presented data. All plasma samples
were counted at the same time to avoid calculated correction
for the decay of 125I. The relative counting error was less than
5%. Serum samples were taken twice a week for the first
2 weeks and then once a week for the following weeks. The
125I concentrations are presented as counts min–1 for a 3 ml
aliquot of plasma.
Immunoadsorption
Serum samples drawn from a normal healthy volunteer (male, age
36 years, weight 86 kg, height 187 cm) after i.v. injection of
2.97 MBq  125I-hCG at 0 h, 2 h, 4 h, 1, 2, 3, 4 days were analysed
using a double antibody direct binding radioimmunoassay.
Monoclonal antibodies (mAb) against the b subunit of hCG (code:
INN-hCG 22) were incubated with 0.4 ml of serum overnight at
4°C. To determine non-specific binding (NSB), 0.4 ml of serum
were incubated with mAb and excess (100 IU) of non-labelled
hCG (Pregnyl®, Organon, The Netherlands). After addition of
0.2 ml immunoadsorbent consisting of goat Ig-antimouse Ig
covalently linked to sepharose 6B (Pharmacia, Uppsala, Sweden)
and incubation for 3 h at room temperature with vigorous agita-
tion, activity was counted in a g-counter (Wallac, Turku, Finland)
for 15 min to determine the total activity (Ta) for each sample. The
tubes were then washed three times using PBS–Tween-80 and
counted for 15 min to determine total bound activity (Bt) and NSB.
Counter background activity (BG) was determined with empty
tubes. As more than 90% of radioactivity after iodination of hCG
is associated with the a-subunit of hCG, this assay will measure
holo-hCG (Markkanen et al, 1980).
All samples were run in duplicate. Mean values were used for
calculation.
Total added activity corrected for background activity (Tacorr)
was calculated as Tacorr = Ta-BG and specifically bound activity as
Bs = Bt-NSB.
High-performance liquid chromatography
Serum samples drawn from a normal healthy volunteer (male, age
40 years, weight 75 kg, height 181 cm) at 2 h, 4 h, 1, 2, 3 and 4
days after injection of 1.75 MBq 125I-hCG were analysed by high-
performance liquid chromatography (HPLC) using a Waters
Deltapac C18 column equilibrated with 0.1% TFA (trifluoracetic
acid) in water, and flow 1 ml min–1. From each serum sample, five
samples of 100 ml each of serum diluted to 50% by sterile saline
(0.9% sodium chloride in water) to prevent clotting of the system,
Bs*100
Per cent Bs of Tacorr was calculated as %Bs = %
Tacor1584 TB Christensen et al
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were applicated to the column consecutively. After the fifth appli-
cation, the chromatography was continued as reverse phase (RP)
chromatography by increasing the concentration of (acetonitrile +
0.1% TFA) from 0% at 5 min to 100% at 20 min. From the 25th
min the column was again eluted with 0.1% TFA.
The outflow from the column was collected in 3-min fractions
in order to determine the low radioactivity. This procedure, unfor-
tunately, loses some resolution in detection of elution time but this
was necessary due to the low count rate which was undetectable
by the HPLC-radioactivity flow detector. The first six fractions
were collected during application of the first four samples. The
remaining ten fractions were collected during the RP period. The
fractions were counted for radioactivity in the energy range
15–75 KeV covering the energy range of 125I for 10 min each using
a  g-well counter (Packard). Samples were analysed in order of
increasing activity to avoid carry over between samples in the
column. Counter background activity was determined on empty
tubes and subtracted from each sample.
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Figure 1 Plasma disappearance of radioactivity and hCG following injection of 125I-hCG in eight normal healthy males
Figure 2 Plasma disappearance of radioactivity and hCG following injection of 125I-hCG in five normal healthy femalesAnalysing unlabelled hCG and 125I-hCG used for i.v. injection,
UV detector (280 nm) and radioactivity detector (15–75 KeV)
were used.
RESULTS
The in vivo elimination of 125I-hCG in normal healthy
subjects
Eight healthy males with a median age of 37 years (range 29–45),
median weight of 78 kg (range 66.4–83.0) and a median height of
185 cm (range 171–195) were injected with a median dose of
2.92 MBq 125I-hCG (range 2.48–3.10). Plasma disappearance of
hCG and radioactivity are shown in Figure 1.
Five healthy females with a median age of 41 years (range
37–42), median weight of 60.0 kg (range 49.2–62.8) and a median
height of 166 cm (range 163–168) were injected with a median
dose of 2.89 MBq 125I-hCG (range 2.63–3.02). Plasma disappear-
ance of hCG and radioactivity are shown in Figure 2.
The plasma disappearance of radioactivity and hCG showed
identical paths from injection of 125I-hCG to day 28 in both males
and females. The plasma disappearance showed an initial fast
elimination phase followed by a phase with a decreasing rate of
disappearance over time. In order to describe the covariation
between  125I-hCG and hCG, measurements were logarithmically
transformed and a linear least squares regression analysis was
applied followed by a t-test procedure for significance. An inter-
cept a = 5.53 (P < 0.0001), slope b = 1.045 (P < 0.0001) and corre-
lation coefficient between 125I-hCG and hCG, r2 = 0.94
(P < 0.0001) were found.
Immunoadsorption
The radioactivity counted on 3 ml of proband serum before injec-
tion of 125I-hCG was identical to background activity. The
percentage of immunoreactive tracer in the serum of a healthy
proband injected with a bolus of 125I-hCG remained constant over
time between 67.1 and 72.1% of total radioactivity (Table 1). Only
after 4 days did it apparently drop to 57%, but this might be due to
the vulnerability of the test system at extremely low count rates.
HPLC
The radioactivity counted on 3 ml of proband serum before injec-
tion of 125I-hCG was identical to background activity. No radio-
activity was detected in the first eight fractions, indicating no free
iodine. The elution pattern of radioactivity in serum samples
drawn from 2 h to 3 days after injection of 125I-hCG is identical to
the elution pattern of 125I-hCG (Figure 3). The radioactivity of
125I-hCG eluted in fractions 13 and 14. The radioactivity in serum
after injection of 125I-hCG eluated in fraction 13 and 14 constant
over time. In Figure 4, the percentage of radioactivity applied to
the column from each sample is shown. The recovery was 101% at
2 h, 92% at 4 h, 91% at day 1, 118% at day 2 and 69% at day 3.
HPLC of 125I-hCG used for injection showed a UV 280 nm and
radioactivity detector signal at the same elution time. HPLC of the
Validation of 125I-hCG as a marker for elimination of hCG 1585
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Table 1
Sample time Tacorr Bt NSB Bs %Bs of Tacorr
2t 52 500 39 884 3499 36 385 69.3%
4t 36 340 27 331 2714 24 617 67.7%
1d 11 245 8726 1049 7677 68.3%
2d 4841 3975 725 3250 67.1%
3d 3146 2882 612 2270 72.2%
4d 2056 1772 598 1172 57.0%
Values for Tacorr, Bt, NSB, and Bs are given in counts per 15 min.
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Figure 3 HPLC of 125I-hCG and serum from normal healthy male following injection of 125I-hCG. Values given as counts per minute (CPM) in each fraction1586 TB Christensen et al
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unlabelled hCG used as raw material for 125I-hCG showed a UV
280 nm detector signal at the same time as radioactivity detector
signal during HPLC of 125I-hCG.
DISCUSSION
We have recently introduced 125I-hCG as an elimination marker in
patients with hCG producing testicular cancer (Christensen et al,
1999). For this purpose, it is important that 125I is associated with
hCG in vivo. Following injection of 125I-hCG in eight healthy
males and five healthy females, the plasma disappearance of
radioactivity (125I-hCG) and immunologically measured hCG
showed identical paths from the day of injection to 28 days after
injection (Figures 1 and 2). The correlation between 125I-hCG and
hCG measurements was found to be statistically significant
(r2 = 0.9443, P < 0.0001). The multiphasic shape of the plasma
disappearance of 125I-hCG and hCG clearly demonstrates the
inappropriateness of calculating one half-life for the elimination
of hCG, as the half-life steadily increases over the 28-day
observation period in this study. Serum hCG values in the eight
healthy males were less than 0.25 IU l–1 and in the five healthy
females less than 0.5 IU l–1 before injection of 125I-hCG. Thus, the
main part of immunologically measured hCG originates from the
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injected 125I-hCG. No side-effects were seen following the injec-
tion of 125I-hCG. The crude hCG was delivered without additives.
Following iodination we were not able, with the present methods,
to find any difference in immunological reactivity or elution
pattern of labelled, unlabelled, or crude hCG material, suggesting
that the hormone remains intact following iodination using the
described iodogen and purification method. Furthermore, we
analysed LH concentrations in serum samples from some normal
healthy males and females after injection of 125I-hCG and were
able to detect a small transient decrease in LH concentrations (data
not presented) suggesting that the labelled hormone was still
hormonally active.
After iodination of hCG, immunoreactivity of 125I-hCG is
maximum 70–80% of the total radioactivity. These percentages are
only found when highly purified hCG (14 000 IU mg–1) is used
for labelling purposes. We used material purified from urine of
pregnant women with an immunological activity of 3000 IU mg–1.
Using double-antibody direct-binding radioimmunassay, we were
able to bind a constant fraction of immunologically active hCG in
serum following injection of 125I-hCG. The bindable fractions
were between 57 and 72% (Table 1, Figure 5). This is comparable
to the known immunoreactivity achievable after iodination of
hCG. At day 4, we were only able to bind 57%, but this could be
due to the vulnerability of the test system at low count rates. The
bindable fraction of 125I-hCG was 49%. This is probably due to a
content of damaged hCG molecules following iodination and
storage (radiation damage). Iodination of hCG destroys two out of
22 epitopes on the hCG molecule as described by Berger et al
(1988). Clearance of radioactive iodide, following ingestion of KI,
damaged hCG molecules, b-hCG and a-hCG produced from urine
of pregnant women, is very rapid from the circulation of man
(Wehmann and Nisula, 1980; Liu et al, 1989). Thus, shortly after
injection of 125I-hCG, the main part of radioactivity in serum will
be associated with hCG, as damaged fractions of protein will be
cleared from the circulation.
HPLC on serum from a healthy normal male following i.v.
injection of 125I-hCG showed no radioactivity in the first eight
fractions, indicating no free iodine. The radioactivity constantly
eluted in fractions 13 and 14 (Figures 3 and 4). HPLC of 125I-hCG
also showed the radioactivity to elute in fractions 13 and 14. Thus,
125I-hCG and radioactivity in serum after injection of
125I-hCG showed an identical elution pattern. As HPLC of crude
hCG and 125I-hCG showed the same elution times, 125I was associ-
ated with hCG in the 125I-hCG used for injection.
In summary, we were able to demonstrate concurrently in each
method the association of 125I with hCG in humans for up to
28 days after i.v. injection of radiolabelled hCG by use of three
different methods. Thus, 125I-hCG is stable in vivo and information
of the expected elimination of hCG can be obtained by following
the elimination of activity in plasma after injection of 125I-hCG.
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